Case Remain for Bal...
Health Care: Drugs
Biosante Pharmaceuticals Inc. (BPAX: NASDAQ)
$1.14 0.00 | 0.00%
05/20/13 - 03:15 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.30M | 435.16K | 2.47M | 1.26M |
| Cost of Sales | 95.00K | 50.00K | 268.75K | 0.00 |
| Gross Operating Profit | 2.21M | 385.16K | 2.21M | 1.26M |
| Selling, General, and Administrative Expenses | 8.23M | 6.98M | 5.94M | 5.67M |
| Research & Development | 16.89M | 44.18M | 39.71M | 13.68M |
| Operating Income before D & A (EBITDA) | -22.91M | -50.78M | -43.44M | -18.10M |
| Depreciation & Amortization | 258.95K | 148.24K | 167.99K | 137.28K |
| Interest Income | 8.54K | 8.33K | 12.66K | 11.65K |
| Other Income - Net | -4.33M | -8.43K | -1.91M | -20.16M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -18.00M |
| Total Income Before Interest Expenses (EBIT) | -27.49M | -50.93M | -45.51M | -47.38M |
| Interest Expense | 348.02K | 681.57K | 688.08K | 147.02K |
| Pre-Tax Income | -27.84M | -51.61M | -46.20M | -47.53M |
| Income Taxes | -121.79K | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -27.72M | -51.61M | -46.20M | -47.53M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -27.72M | -51.61M | -46.20M | -47.53M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -27.72M | -51.61M | -46.20M | -47.53M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-27.72M | -51.61M | -46.20M | -38.53M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -27.72M | -51.61M | -46.20M | -47.53M |
| Basic EPS from Continuing Ops. | -1.27 | -3.12 | -4.20 | -8.40 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.27 | -3.12 | -4.20 | -8.40 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.27 | -3.12 | -4.20 | -8.40 |
| Basic Normalized Net Income/Share | -1.27 | -3.12 | -4.20 | -6.81 |
| EPS fr Continuing Ops. | -1.27 | -3.12 | -4.20 | -8.40 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.27 | -3.12 | -4.20 | -8.40 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.27 | -3.12 | -4.20 | -8.40 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.27 | -3.12 | -4.20 | -6.81 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with BPAX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorHot Biotech Stocks Traded b...
- UserSaveyn walter
- User2012_03
- Userwayne120
- ContributorBreakout Stocks Of The Week...
- UserDunDon1
- Contributor6 Drug Stocks Unworthy of B...
Latest BPAX Headlines from TheStreet
- The Worst Biotech CEO of 2012 Is... 12.07.12 | 09:12 am
- Your Vote Counts: Who Is the Worst Biotech CEO of 2012? 12.04.12 | 08:12 am
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
- BioSante Execs Use Failed Libigel To Keep Paychecks Rolling In 06.11.12 | 09:06 am
- Biosante Stock Gaps Down On Today's Open (BPAX) 06.01.12 | 09:06 am
- Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon 02.29.12 | 06:02 am
- Transocean, Netflix, BioSante Are Market Movers 02.27.12 | 05:02 pm
- Biotech Stock Mailbag: Vivus, Chelsea, BioCryst 02.17.12 | 05:02 am
Press Releases for BPAX
- Ceregene Reports Data From Parkinson's Disease Phase 2b Study - PR Newswire 04.19.13 | 02:04 pm
- BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders To Vote “FOR” Proposed Merger With ANI Pharmaceuticals, Inc. - Business Wire 03.19.13 | 09:03 am
- BioSante Pharmaceuticals Announces Adjournment Of Its Stockholders Meeting Until April 12, 2013 - Business Wire 03.15.13 | 04:03 pm
- Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial - PR Newswire 03.13.13 | 07:03 am
- Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger - Business Wire 03.04.13 | 09:03 am
- BioSante Pharmaceuticals Provides Merger Update And Reports 2012 Financial Results - Business Wire 03.01.13 | 09:03 am
- Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones In Recommending “FOR” BioSante/ANI Merger - Business Wire 02.26.13 | 09:02 am
- Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante And ANI Merger - Business Wire 02.19.13 | 09:02 am
- BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Special Meetings Of Stockholders To Consider Proposed Merger - Business Wire 01.22.13 | 04:01 pm
- BioSante Pharmaceuticals Reports Third Quarter Financial Results And Merger Update - Business Wire 11.08.12 | 04:11 pm
Partner Headlines for BPAX
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Healthcare Biz Recap: Complete Genomics CUTS Costs, Abbott Labs Teams Up - Wall St. Cheat Sheet 06.06.12 | 08:06 am
- Alimera Sciences: An Upcoming Catalyst Should Make For A Nice Stock Gain - Seeking Alpha 03.26.12 | 09:03 am
- Bio-Pharma Watch List: 2 Week Report Card - Seeking Alpha 03.12.12 | 09:03 am
- What BioSante's Balance Sheet Says About Future R&D - Seeking Alpha 03.01.12 | 08:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- Singular Research Drops Coverage on BioSante Pharma After LibGel Results - Benzinga 12.16.11 | 04:12 pm
- Singular Research Reiterates BioSante Pharmaceuticals Buy, Maintains PT - Benzinga 12.13.11 | 01:12 pm
